Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGFβ1 and miR-29 pathways
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGFβ1 and miR-29 pathways
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-03-14
DOI
10.1038/srep23010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interleukin-6 mediates exercise preconditioning against myocardial ischemia reperfusion injury
- (2015) Graham Ripley McGinnis et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension
- (2015) Germán E. González et al. JOURNAL OF HYPERTENSION
- Inhibition of PKC-θ preserves cardiac function and reduces fibrosis in streptozotocin-induced diabetic cardiomyopathy
- (2014) Zhao Li et al. BRITISH JOURNAL OF PHARMACOLOGY
- MicroRNA-29 Fine-tunes the Expression of Key FOXA2-Activated Lipid Metabolism Genes and Is Dysregulated in Animal Models of Insulin Resistance and Diabetes
- (2014) C. L. Kurtz et al. DIABETES
- Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy
- (2014) Wen-ke Wang et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- miR-29b as a Therapeutic Agent for Angiotensin II-induced Cardiac Fibrosis by Targeting TGF-β/Smad3 signaling
- (2014) Yang Zhang et al. MOLECULAR THERAPY
- Regulation of Cardiac Expression of the Diabetic Marker MicroRNA miR-29
- (2014) Nicholas Arnold et al. PLoS One
- microRNAs in cardiac regeneration and cardiovascular disease
- (2013) GengZe Wu et al. Science China-Life Sciences
- MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor-β1 Pathway
- (2012) Zhenwei Pan et al. CIRCULATION
- Diabetic cardiomyopathy
- (2012) BR Goyal et al. HUMAN & EXPERIMENTAL TOXICOLOGY
- MicroRNA-24 regulates cardiac fibrosis after myocardial infarction
- (2012) Jue Wang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Inhibition of miR-29 by TGF-beta-Smad3 Signaling through Dual Mechanisms Promotes Transdifferentiation of Mouse Myoblasts into Myofibroblasts
- (2012) Liang Zhou et al. PLoS One
- Plasma levels of tumor necrosis factor-α and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase
- (2011) Cho-Kai Wu et al. CRITICAL CARE MEDICINE
- TGF- /Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29
- (2011) W. Qin et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Interleukin 6 Mediates Myocardial Fibrosis, Concentric Hypertrophy, and Diastolic Dysfunction in Rats
- (2010) Giselle C. Meléndez et al. HYPERTENSION
- MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases
- (2009) Zhen-wei Pan et al. ACTA PHARMACOLOGICA SINICA
- WISP1, a Pro-mitogenic, Pro-survival Factor, Mediates Tumor Necrosis Factor-α (TNF-α)-stimulated Cardiac Fibroblast Proliferation but Inhibits TNF-α-induced Cardiomyocyte Death
- (2009) Kaliyamurthi Venkatachalam et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
- (2008) Thomas Thum et al. NATURE
- Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
- (2008) E. van Rooij et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started